Literature DB >> 26417522

Quantitative imaging of light-triggered doxorubicin release.

Jeremy Kress1, Daniel J Rohrbach1, Kevin A Carter2, Dandan Luo2, Shuai Shao2, Shashikant Lele3, Jonathan F Lovell2, Ulas Sunar1.   

Abstract

The efficacy of chemotherapy is related, in large part, to the concentration of drug that reaches tumor sites. Doxorubicin (DOX) is a common anti-cancer drug that is also approved for use in liposomal form for the treatment of ovarian cancer. We recently developed a porphyrin-phospholipid (PoP)-liposome system that enables on demand release of DOX from liposomes using near infrared irradiation to improve DOX bioavailability. Owing to its intrinsic fluorescence, it is possible, and desirable, to quantify DOX concentration and distribution, preferably noninvasively. Here we quantified DOX distribution following light-triggered drug release in phantoms and an animal carcass using spatial frequency domain imaging. This study demonstrates the feasibility of non-invasive quantitative mapping of DOX distributions in target areas.

Entities:  

Keywords:  (170.0110) Imaging systems; (170.0170) Medical optics and biotechnology; (170.3880) Medical and biological imaging; (170.6935) Tissue characterization

Year:  2015        PMID: 26417522      PMCID: PMC4574678          DOI: 10.1364/BOE.6.003546

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  37 in total

1.  Analytical model for extracting intrinsic fluorescence in turbid media.

Authors:  J Wu; M S Feld; R P Rava
Journal:  Appl Opt       Date:  1993-07-01       Impact factor: 1.980

2.  Experimental validation of an inverse fluorescence Monte Carlo model to extract concentrations of metabolically relevant fluorophores from turbid phantoms and a murine tumor model.

Authors:  Chengbo Liu; Narasimhan Rajaram; Karthik Vishwanath; Tony Jiang; Gregory M Palmer; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

3.  Quantitative fluorescence imaging of protoporphyrin IX through determination of tissue optical properties in the spatial frequency domain.

Authors:  Rolf B Saager; David J Cuccia; Steve Saggese; Kristen M Kelly; Anthony J Durkin
Journal:  J Biomed Opt       Date:  2011-12       Impact factor: 3.170

4.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

5.  Model-based analysis of clinical fluorescence spectroscopy for in vivo detection of cervical intraepithelial dysplasia.

Authors:  Sung K Chang; Nena Marin; Michele Follen; Rebecca Richards-Kortum
Journal:  J Biomed Opt       Date:  2006 Mar-Apr       Impact factor: 3.170

6.  Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy.

Authors:  Gregory M Palmer; Richard J Boruta; Benjamin L Viglianti; Lan Lan; Ivan Spasojevic; Mark W Dewhirst
Journal:  J Control Release       Date:  2009-11-05       Impact factor: 9.776

7.  Recovery of intrinsic fluorescence from single-point interstitial measurements for quantification of doxorubicin concentration.

Authors:  Timothy M Baran; Thomas H Foster
Journal:  Lasers Surg Med       Date:  2013-08-23       Impact factor: 4.025

8.  In vivo quantification of fluorescent molecular markers in real-time by ratio imaging for diagnostic screening and image-guided surgery.

Authors:  A Bogaards; H J C M Sterenborg; J Trachtenberg; B C Wilson; L Lilge
Journal:  Lasers Surg Med       Date:  2007-08       Impact factor: 4.025

9.  Porphyrin-phospholipid liposomes permeabilized by near-infrared light.

Authors:  Kevin A Carter; Shuai Shao; Matthew I Hoopes; Dandan Luo; Bilal Ahsan; Vladimir M Grigoryants; Wentao Song; Haoyuan Huang; Guojian Zhang; Ravindra K Pandey; Jumin Geng; Blaine A Pfeifer; Charles P Scholes; Joaquin Ortega; Mikko Karttunen; Jonathan F Lovell
Journal:  Nat Commun       Date:  2014-04-03       Impact factor: 14.919

10.  Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer.

Authors:  Michelle Longmire; Nobuyuki Kosaka; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Sci       Date:  2009-03-16       Impact factor: 6.716

View more
  6 in total

1.  Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy.

Authors:  Kevin A Carter; Dandan Luo; Aida Razi; Jumin Geng; Shuai Shao; Joaquin Ortega; Jonathan F Lovell
Journal:  Theranostics       Date:  2016-10-01       Impact factor: 11.556

2.  A dual-channel endoscope for quantitative imaging, monitoring, and triggering of doxorubicin release from liposomes in living mice.

Authors:  Jeremy Kress; Daniel J Rohrbach; Kevin A Carter; Dandan Luo; Chien Poon; Semra Aygun-Sunar; Shuai Shao; Shashikant Lele; Jonathan F Lovell; Ulas Sunar
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

3.  Mechanisms of Light-induced Liposome Permeabilization.

Authors:  Dyego Miranda; Jonathan F Lovell
Journal:  Bioeng Transl Med       Date:  2016-09-28

4.  Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer.

Authors:  Song Lou; Zongmin Zhao; Micah Dezort; Taylor Lohneis; Chenming Zhang
Journal:  ACS Omega       Date:  2018-08-15

5.  Optoacoustic properties of Doxorubicin - A pilot study.

Authors:  Melanie A Kimm; Claudia Gross; Xose Luis Déan-Ben; Avihai Ron; Ernst J Rummeny; Hsiao-Chun Amy Lin; Carsten Höltke; Daniel Razansky; Moritz Wildgruber
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

6.  Labeling of Erythrocytes by Porphyrin-Phospholipid.

Authors:  Sunanda Kumar; Dawei Jiang; Boyang Sun; Kaelyn V Seeley; Jonathan W Engle; Zachary Sia; Xuedan He; Sriram Neelamegham; Weibo Cai; Jonathan F Lovell
Journal:  Adv Nanobiomed Res       Date:  2020-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.